Informing sample size and power calculations for clone-censor-weight analyses: a Monte Carlo simulation study of the variance inflation factor relative to the underlying target trial.

IF 5.8 2区 医学 Q1 HEALTH CARE SCIENCES & SERVICES
Peter C Austin
{"title":"Informing sample size and power calculations for clone-censor-weight analyses: a Monte Carlo simulation study of the variance inflation factor relative to the underlying target trial.","authors":"Peter C Austin","doi":"10.1016/j.jclinepi.2026.112576","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clone-censor-weighting (CCW) is a causal inference method used in target trial emulation in settings in which the time of application of the treatment occurs during follow-up. An important component of study design is determining the sample size required for a specified level of statistical power or to determine the statistical power associated with a specific sample size. Determining statistical power is relatively straightforward for the underlying randomized controlled trial (RCT) that one is emulating. In contrast, conducting power and sample size calculations for observational studies that employ CCW is not straightforward because the analysis incorporates inverse probability of censoring weights, which are only known at the analysis phase, and not during the design phase.</p><p><strong>Methods: </strong>Monte Carlo simulations (270 scenarios varying sample size, treatment prevalence, threshold for defining early treatment, and covariate-treatment odds ratios) were used to estimate the variance inflation factor (VIF) of a CCW analysis compared to the underlying target RCT, across two estimands: the risk difference and the relative risk.</p><p><strong>Results: </strong>In settings with 10 baseline covariates, the use of a CCW design tended to result in more precise estimation of risk differences and relative risks compared to the underlying RCT when the magnitude of confounding was low to moderate. The magnitude of the VIF depended on treatment prevalence, sample size, the time horizon at which risk was estimated, and the strength of the baseline covariates' association with treatment initiation. In secondary simulations, it was observed that the VIF comparing a CCW design to the underlying RCT tended to increase as the number of baseline covariates increased.</p><p><strong>Conclusions: </strong>Researchers designing CCW studies can use the simulation results and the accompanying R code, available in a public GitHub repository, to obtain study-specific VIF estimates for incorporation into a priori power calculations.</p>","PeriodicalId":51079,"journal":{"name":"Journal of Clinical Epidemiology","volume":" ","pages":"112576"},"PeriodicalIF":5.8000,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jclinepi.2026.112576","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clone-censor-weighting (CCW) is a causal inference method used in target trial emulation in settings in which the time of application of the treatment occurs during follow-up. An important component of study design is determining the sample size required for a specified level of statistical power or to determine the statistical power associated with a specific sample size. Determining statistical power is relatively straightforward for the underlying randomized controlled trial (RCT) that one is emulating. In contrast, conducting power and sample size calculations for observational studies that employ CCW is not straightforward because the analysis incorporates inverse probability of censoring weights, which are only known at the analysis phase, and not during the design phase.

Methods: Monte Carlo simulations (270 scenarios varying sample size, treatment prevalence, threshold for defining early treatment, and covariate-treatment odds ratios) were used to estimate the variance inflation factor (VIF) of a CCW analysis compared to the underlying target RCT, across two estimands: the risk difference and the relative risk.

Results: In settings with 10 baseline covariates, the use of a CCW design tended to result in more precise estimation of risk differences and relative risks compared to the underlying RCT when the magnitude of confounding was low to moderate. The magnitude of the VIF depended on treatment prevalence, sample size, the time horizon at which risk was estimated, and the strength of the baseline covariates' association with treatment initiation. In secondary simulations, it was observed that the VIF comparing a CCW design to the underlying RCT tended to increase as the number of baseline covariates increased.

Conclusions: Researchers designing CCW studies can use the simulation results and the accompanying R code, available in a public GitHub repository, to obtain study-specific VIF estimates for incorporation into a priori power calculations.

告知克隆-审查-权重分析的样本大小和功率计算:相对于潜在目标试验的方差膨胀因子的蒙特卡罗模拟研究。
背景:克隆审查员加权(CCW)是一种用于目标试验模拟的因果推理方法,在这种情况下,治疗的应用时间发生在随访期间。研究设计的一个重要组成部分是确定特定统计能力水平所需的样本量或确定与特定样本量相关的统计能力。对于正在模拟的基础随机对照试验(RCT)来说,确定统计能力相对简单。相比之下,在使用常规化学武器的观测研究中进行功率和样本量计算并不简单,因为分析包含了审查权值的逆概率,而这些权值仅在分析阶段而不是在设计阶段才知道。方法:使用蒙特卡罗模拟(270个不同样本量、治疗流行率、定义早期治疗的阈值和协变量治疗优势比的场景)来估计CCW分析与潜在目标RCT相比的方差膨胀因子(VIF),通过两个估计:风险差异和相对风险。结果:在具有10个基线协变量的情况下,与基础RCT相比,当混杂程度为低至中等时,CCW设计的使用倾向于更精确地估计风险差异和相对风险。VIF的大小取决于治疗流行程度、样本量、估计风险的时间范围,以及基线协变量与治疗开始的关联强度。在二次模拟中,观察到将CCW设计与基础RCT进行比较的VIF倾向于随着基线协变量数量的增加而增加。结论:设计CCW研究的研究人员可以使用模拟结果和随附的R代码(可在公共GitHub存储库中获得)来获得研究特定的VIF估计,并将其纳入先验功率计算。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Epidemiology
Journal of Clinical Epidemiology 医学-公共卫生、环境卫生与职业卫生
CiteScore
12.00
自引率
6.90%
发文量
320
审稿时长
44 days
期刊介绍: The Journal of Clinical Epidemiology strives to enhance the quality of clinical and patient-oriented healthcare research by advancing and applying innovative methods in conducting, presenting, synthesizing, disseminating, and translating research results into optimal clinical practice. Special emphasis is placed on training new generations of scientists and clinical practice leaders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书